TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Modifiers of Tenofovir in the Female Genital Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, or transgender female with a cervix, aged 18-35 years old~* HIV-positive~* Stable on antiretroviral regimen containing TDF for at least 2 weeks at time of enrollment.~* Virally suppressed (HIV-RNA copies \<50 copies/mL) for at least 6 months at time of enrollment.~* Willing to refrain from vaginal intercourse and use of vaginal devices such as douches and sex toys within 72 hours of the biopsy visit.~* Willing and able to give signed informed consent.~Exclusion Criteria:~* Currently pregnant or previous pregnancy within 3 months of enrollment~* Currently breast feeding~* Symptomatic vaginal infection within 2 weeks prior to enrollment~* Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynecologic surgery within 90 days prior to enrollment~* History of vulvar/vaginal/ cervical dysplasia, neoplasia or cancer, atypical squamous cells of undetermined significance, condyloma, or human papilloma virus (HPV) in the past year~* Use of oral and/or vaginal preparations of antibiotic or antifungal medications within 30 days prior to the enrollment visit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Depo-Provera (Type: None): None
- Non-hormonal contraception (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>/=18 years of age~* histologically confirmed metastatic melanoma (Stage IV, AJCC)~* patients must have completed and failed at least one prior standard of care regimen (e.g. DTIC, temozolomide, etc.)~* BRAF V600E positive mutation (by Roche CoDx BRAF mutation assay)~* measurable disease by RECIST criteria~* negative pregnancy test and, for fertile men and women, effective contraception during treatment and for 6 months after completion~Exclusion Criteria:~* active CNS metastases on CT/MRI within 28 days prior to enrollment~* history of or known carcinomatous meningitis~* previous treatment with BRAF (sorafenib allowed) or MEK inhibitor~* cardiac dysrhythmias \>2 NCI CTCAE or treatment with drugs with dysrhythmic potential~* uncontrolled hypertension(\>150/100mmHg) despite optimal medical therapy~* infectious disease including HIV, HBV and HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention for Bipolar Type-II Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Bipolar II Depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Not currently on drug therapy for type 2 diabetes~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Pregnancy or lactation~* Type 1 diabetes~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular conditions~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have confirmed acute symptomatic Pulmonary Embolism (PE) with or without symptomatic deep vein thrombosis (DVT)~* A PE participant diagnosed in the Emergency Department (ED) who is deemed to be at low risk of clinical deterioration as determined by the Hestia criteria~* Have no contraindications to and be able to complete randomized treatment and all study assessments~* Have a life expectancy of at least 6 months~* Must be willing and able to adhere to the prohibitions and restrictions specified in this protocol~Exclusion Criteria:~* Having received any Combined P-gp (P-glycoprotein) and strong CYP3A4 (Cytochrome P450) inhibitors (such as but not limited to ketoconazole, telithromycin or protease inhibitors) use within 4 days before randomization, or planned use during the study. Itraconazole use within 7 days before randomization or planned use during the study~* Having received any Combined P-gp and strong CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort) use within 2 weeks before randomization or planned use during the study~* Who Has contraindications to the use of any anticoagulant therapy (example, bleeding diathesis, history of gastrointestinal bleeding within 1 year or coagulopathy documented at Screening)~* Who Has known allergies, hypersensitivity, or intolerance to rivaroxaban or its excipients~* Woman who is pregnant, or breast-feeding, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
- local Standard-of-care (Type: EXPERIMENTAL): Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-emptive Analgesics in Orthodontic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Orthodontic patient presenting for orthodontic treatment~Exclusion Criteria:~* History of taking an analgesic in the past six hours~* Hypersensitivity to ibuprofen or acetaminophen~* Aspirin-sensitive asthma~* Renal or liver impairment~* History of GI bleeding or ulcers~* Cardiovascular disease, recent myocardial infarction, heart failure, or coronary artery bypass graft surgery~* Currently taking antibiotics or other medications for a chronic systemic disease~* Bleeding disorder~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Acetaminophen (Type: ACTIVE_COMPARATOR): Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
- Ibuprofen (Type: ACTIVE_COMPARATOR): Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
- Acetaminophen and Ibuprofen (Type: EXPERIMENTAL): Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Insulin naive Type 2 diabetes~* Currently treated with OADs alone or combined with other treatment for at least 3 months~* BMI below 40 kg/m2 and body weight below 125 kg~* HbA1c greater than or equal to 8%~Exclusion Criteria:~* Inability to tolerate metformin or contradictions to its use~* Pregnant, breastfeeding or intention of becoming pregnant~* Allergy to any of the trial products~* Inability or unwillingness to perform SMBG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* =or \> 20 years~* Admission for General anesthesia for RFCA or cryoablation procedure~Exclusion Criteria:~* No severe adverse effect history or hypersensitivity of benzodiazepines or its additives~* Acute alcoholic intoxication state~* Coma or shock state due to other condition than heart problem.~* Acute narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 105 Years
- Healthy Volunteers: f

Study Arms:
- Remimazolam (Type: EXPERIMENTAL): General anesthesia with remimazolam-remifentanil TIVA.
- Desflurane (Type: NO_INTERVENTION): General anesthesia with maintaining with desflurane (induction:PPF, remifentanil CIV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fibre Products on Appetite and Weight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers aged between 21 and 65 years~Exclusion Criteria:~* Weight change of more than 3kg in the preceding 2 months~* Current smokers~* Substance abuse~* Excess alcohol intake~* Pregnancy~* Diabetes~* Cardiovascular disease~* Cancer~* Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome~* Kidney disease~* Liver disease~* Pancreatitis~* Use of medications including: anti inflammatory drugs or steroids, cholesterol lowering medication, androgens, phenytoin, erythromycin or thyroid hormones.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Propionate ester (Type: EXPERIMENTAL): None
- Fermentable control (Type: PLACEBO_COMPARATOR): None
- Non fermentable control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥ 18 years of age.~2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.~3. QMG score ≥12 at Screening and Baseline.~Other, more specific inclusion criteria are defined in the protocol.~Exclusion Criteria:~1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.~2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.~3. Thymectomy performed \< 12 months prior to screening.~4. Total IgG level \<6 g/L (at screening).~5. Absolute neutrophil count \<1500 cells/mm3(at screening).~Other, more specific exclusion criteria are defined in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen A (Type: EXPERIMENTAL): RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
- Regimen B (Type: EXPERIMENTAL): RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate pre-transplant renal dysfunction as defined serum creatinine levels higher than 1.5 mg/dl or eGFR (MDRD-4) \<60ml/min.~* First liver transplant, including splits liver transplant.~* Patients aged 18-70 years~* Without a prior contraindication for protocol biopsy of allograft.~Exclusion Criteria:~* Multiorgan transplantation and/or liver transplant from DCD and/or with ABO incompatibility.~* Uncontrolled concomitant infections (including HIV seropositivity) and/or diarrhoea, vomiting or active gastric ulcer.~* Fulminant hepatic insufficiency as first indication for liver transplant~* Hemodynamic instability prior to liver transplant.~* Recipient presenting present or previous neoplasia, except for non-metastatic basal or squamous cutaneous carcinoma or localized hepatocarcinoma with diameter \<5 cm or \< 3 known lesions with diameter \<3 cm.~* Intolerance to study medication.~* Patients having received vaccination with attenuated living vaccines within the previous 4 weeks.~* Severe leukopenia (\< 1.2 X 10E9/L) and/or thrombocytopenia (\< 50x10E9/L) and/or lymphocyte counts (CD2+/CD3+) less than 10 cells/µl.~* Significant comorbidity.~* Breastfeeding or female patients at fertile age without negative pregnancy test and accepting the use of reliable fertility control method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Basiliximab (Type: NO_INTERVENTION): Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
- ATeGe-Fresenius (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients with moderate or severe active Crohn's disease who are not responding well to conventional therapy and receive Humira will be enrolled in the survey~Exclusion Criteria:~Contraindications according to the Package Insert~* Patients who have serious infections~* Patients who have tuberculosis~* Patients with a history of hypersensitivity to any ingredient of Humira~* Patients who have demyelinating disease or with a history of demyelinating disease~* Patients who have congestive cardiac failure

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Humira (Type: None): Participants who were prescribed Humira per approved prescribing information of Humira in Japan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~≥ 18 years of age~Potassium ≥5.8 mmol/L~Exclusion Criteria:~Possible pseudohyperkalaemia~Hyperkalaemia caused by any condition for which a therapy directed against the underlying cause of hyperkalaemia would be a better treatment option than treatment with insulin and glucose.~Dialysis session expected within 4h after randomization~Treated with any therapy intended to lower S-K between arriving at the hospital and randomization during Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- ZS+insulin+glucose (Type: EXPERIMENTAL): ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
- Placebo+insulin+glucose (Type: PLACEBO_COMPARATOR): Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA class 1 or 2~2. Adults over the age of 20 and under 70~3. Patients undergoing robot-assisted laparoscopic radical prostatectomy~4. Patients that have given informed consent~Exclusion Criteria:~1. Patients with known ophthalmic diseases (glaucoma, diabetic retinopathy, cataract, retinal detachment)~2. Patients with history of ophthalmic surgery~3. Patients with high baseline intraocular pressure (over 30 mmHg)~4. Patients with active cardiac conditions (unstable angina, congestive heart failure)~5. Patients with uncontrolled hypertension (diastolic blood pressure \> 110 mmHg)~6. Patients with history of allergic reactions to propofol~7. Illiterate patients

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Inhalational anesthesia group (Type: ACTIVE_COMPARATOR): None
- Total intravenous anesthesia group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between 50 and 75 years with a defined complete rotator cuff tear as compatible clinical and confirmation by magnetic resonance imaging (MRI).~* Minimum of 3 months of failed conservative treatment (anti-inflammatory, physical therapy and infiltration with corticosteroids)~Exclusion Criteria:~* Refusal to participate or informed consent,~* Revision surgery,~* Partial repair,~* Patients with shoulder osteoarthritis\> 2~* Advanced fat infiltration of the rotator cuff muscles (STAGE 3 or 4)~* Systemic or rheumatoid arthritis,~* Uncontrolled diabetes, (patients for whom surgery is contraindicated in the preoperative evaluation by the clinician and anesthesiologist)~* Acute or chronic infections of the shoulder to be operated on~* Ongoing cancer chemotherapy therapies~* Sepsis, septic arthritis, osteomyelitis or other ongoing infectious processes;~* Previous operations on the affected shoulder,~* Patients with autoimmune diseases;~* Pregnant

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arthroscopic rotator cuff repair and platelet rich plasma (Type: EXPERIMENTAL): A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.
- Arthroscopic rotator cuff repair (Type: ACTIVE_COMPARATOR): A standard double-row arthroscopic rotator cuff repair will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete